Nutrition Science News




Hishida, et al.  Antitumour activity exhibited by orally administered extracts from Maitake. Chem Pharm Bull. Toxyo 1988.

Nanba, H. A. Hamaguchi & H Kuroda 1987.  The chemical structure of an antitumour polysaccaride in fruit bodies of Maitake. Chem. Pharm. Bull. 35 (3): 1162-1168

Nanba, H. 1993. Antitumour activity of orally administered D-Fraction from Maitake. J. Naturopathic Med. 1(4); 10-15.

"The cancer metastasis was prevented by 91.3% by the oral administration of D-Fraction.  the Maitake-fed group also demonstrated an impressive 81.3% prevention, indicating Maitake's strong ability to inhibit cancer metastasis.   Also, the results of the second test indicate its ability to prevent carcinogenesis in normal cells."--Hiroaki Nanba 1995.

Ohno, N. K. Ito. T. Takeyama, I. Suzuki, K. Sato, S. Oikawa & T. Miyazaki 1985. Chem. Pharm. Bull. 33; 3395

Mizuno, T. K Ohsawa, N. Hagiwara & R. Kuboyama 1986. Agric. Biol. Chem. 50; 1679.

Maitake D-Fraction:

Various studies show Maitake D-Fraction is superior to Lantinan (b-1,3 glucan extracted from Shiitake), the ant-cancer drug approved by the Japanese FDA (Mori, K. Toyomatsu 1986. Antitumour activities of edible mushroooms by oral administration. Int Symp. Sci. Tech. Pennsylvania University).

A non-controlled clinical study using Maitake D-Fraction indicates impressive response rate particularly in breast, lung, liver, prostate cancers & brain tumours. H. Nanba, Explore! vol 6. No 5 1995.

It has been confirmed useful when taken in conjunction with chemo' agents not only to improve the agent's positive benefits in inhibiting cancer growth but also to ameliorate many negative side effects of the agents.  H. Nanba.

See: Herbs for cancer

[Home]  [Cancer]  [AIDS]  [Heart Disease] [Medical Politics]  [Vaccines] [Dental]